CONGRESS ABSTRACT

Background and Aims We evaluated the feasibility of an early triple lipid lowering therapy (LLT) with PCSK9 inhibitors in patients with acute coronary syndromes (ACS).    Methods In this multicenter experience, we consecutively enrolled patients with ACS from July 2023 to July 2024. The prescribed LLT was evaluated at…

Homozygous Autosomal Recessive Hypercholesterolemia (ARH) is a rare form of genetic hypercholesterolemia caused by mutations in low density lipoprotein receptor adaptor protein 1(LDLRAP1)characterized by very high levels of low-density-lipoprotein-cholesterol (LDL-C),leading to aggressive and premature atherosclerotic cardiovascular disease.The gold standard treatment is LDL-apheresis.Novel therapies are thus needed for this severe…

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce the risk of major cardiovascular events and cardiovascular death in patients with type 2 diabetes mellitus (T2DM). Recent studies suggest a potential antiarrhythmic effect associated with GLP-1 receptor activation. However, the impact of this drug class on…

Background: Bempedoic acid (BA), an adenosine triphosphate-citrate lyase inhibitor, effectively reduces low-density lipoprotein cholesterol (LDL-C) and cardiovascular (CV) risk, as shown in randomised clinical trials. However, real-world evidence documenting its use in clinical practice remains limited. Methods: MILOS, a European, prospective, observational study (NCT04579367), evaluates the effectiveness and safety…